Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014864 | 0.87 | FAAH (0.33) | CES1FAAHCES2PLA2G6LMNA | |
| SCHEMBL23014898 | 0.83 | LMNA (0.36) | CES1FAAHCES2PLA2G6LMNA | |
| SCHEMBL1014316 | 0.81 | — | — | |
| SCHEMBL2043689 | 0.80 | PTPN7 (0.42) | CES1FAAHCES2LMNA | |
| SCHEMBL9548439 | 0.80 | PTPN7 (0.42) | CES1FAAHCES2LMNA | |
| SCHEMBL1017045 | 0.79 | — | — | |
| SCHEMBL1015598 | 0.79 | — | — | |
| SCHEMBL1015892 | 0.79 | TRPA1 (0.35) | LMNA | |
| SCHEMBL8024226 | 0.78 | LMNA (0.39) | CES1FAAHCES2LMNA | |
| SCHEMBL1015808 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | claimed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | CES1 33/4885FAAH 445/4885CES2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.